1st World Congress on Ga-68 and Peptide Receptor Radionuclide Therapy

THERANOSTICS – on the Way to Personalized Medicine

Since 1997, when he first used the radiolabeled peptide Y-90 DOTATOC (a somatostatin anlogue) to treat a 15-year-old boy with a rare neuroendocrine tumor, called paraganglioma, and saw the boy go from being wheelchair-bound and in terrible pain to a young man of 20 who was walking and playing soccer, Prof. Dr. med. Richard P. Baum has been passionate about Peptide Receptor Radionuclide Therapy (PRRNT). To share his enthusiasm

Read more: 1st World Congress on Ga-68 and Peptide Receptor...

January 2011 - European Neuroendocrine Tumor Society has certified Zentralklink Bad Berka as an ENETS Centers of Excellence.  The certification states that center meets all quality standards defined by ENETS for interdisciplinary diagnostics, medical treatment and aftercare of patients with neuroendocrine tumors.  Click here to download a copy of the certificate.

"It shrinks tumors in about a third of cases significantly, and it lasts on average about two to three years," said Strosberg."Even though you get tumor shrinkage, you mostly get disease progression that stabilizes," said Dr. Thomas O'Dorisio, professor of medicine at the University of Iowa in Iowa City. Experts believe the FDA will eventually approve PRRT.

"The data are coming out slowly. There's never been a phase 3 clinical trial, and that's why it's not okayed yet," said O'Dorisio. "It's a new, experimental treatment, and it has to go through the same approval process as all drugs," said Ayala.

From ABC News